
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
PP&E Gross
OSE Immunotherapeutics SA
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
PP&E Gross
€3.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
PP&E Gross
€8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
PP&E Gross
€11.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
24%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's PP&E Gross?
PP&E Gross
3.6m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's PP&E Gross amounts to 3.6m EUR.
What is OSE Immunotherapeutics SA's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
5%
Over the last year, the PP&E Gross growth was -15%. The average annual PP&E Gross growth rates for OSE Immunotherapeutics SA have been 9% over the past three years , 5% over the past five years .